Download PDF
Horm Metab Res 2015; 47(06): 418-426
DOI: 10.1055/s-0035-1548868
Review
© Georg Thieme Verlag KG Stuttgart · New York

Renin and Aldosterone Measurements in the Management of Arterial Hypertension

A. Viola
1   Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, Torino, Italy
,
S. Monticone
1   Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, Torino, Italy
,
J. Burrello
1   Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, Torino, Italy
,
F. Buffolo
1   Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, Torino, Italy
,
M. Lucchiari
2   Clinical Chemistry Laboratory, University of Torino, Torino, Italy
,
F. Rabbia
1   Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, Torino, Italy
,
T. A. Williams
1   Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, Torino, Italy
,
F. Veglio
1   Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, Torino, Italy
,
G. Mengozzi
2   Clinical Chemistry Laboratory, University of Torino, Torino, Italy
,
P. Mulatero
1   Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, Torino, Italy
› Author Affiliations
Further Information

Publication History

received 23 July 2014

accepted 12 March 2015

Publication Date:
08 May 2015 (online)

Also available at
   Permissions and Reprints

Abstract

Renin-angiotensin-aldosterone system (RAAS) is recognized as the main regulatory system of hemodynamics in man, and its derangements have a key role in the development and maintenance of arterial hypertension. Classification of the hypertensive states according to different patterns of renin and aldosterone levels (“RAAS profiling”) allows the diagnosis of specific forms of secondary hypertension and may identify distinct hemodynamic subsets in essential hypertension. In this review, we summarize the application of RAAS profiling for the diagnostic assessment of hypertensive patients and discuss how the pathophysiological framework provided by RAAS profiling may guide therapeutic decision-making, especially in the context of uncontrolled hypertension not responding to multi-therapy.

Key words

arterial hypertension - rennin - aldosterone - Laragh’s hypothesis - therapy
 

  • References

  • 1 Basso N, Terragno NA. History About the Discovery of the Renin-Angiotensin System. Hypertension 2001; 38: 1246-1249
    CrossrefPubMedGoogle Scholar
  • 2 Castrop H, Höcherl K, Kurtz A, Schweda F, Todorov V, Wagner C. Physiology of kidney renin. Physiol Rev 2010; 90: 607-673
    CrossrefPubMedGoogle Scholar
  • 3 Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803
    CrossrefPubMedGoogle Scholar
  • 4 Weir MR, Dzau VJ. The Renin-Angiotensin-Aldosterone System: A Specific Target for Hypertension Management. Am J Hypertens 1999; 12: 205S-213S
    PubMedGoogle Scholar
  • 5 Takahashi H. Upregulation of the Renin-Angiotensin-Aldosterone-Ouabain System in the Brain Is the Core Mechanism in the Genesis of All Types of Hypertension. Int J Hypertens 2012; 242786
    PubMedGoogle Scholar
  • 6 Gavras H, Brunner HB, Vaughan ED, Laragh JH. Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science 1973; 180: 1369-1371
    CrossrefPubMedGoogle Scholar
  • 7 Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med 1973; 55: 261-274
    CrossrefPubMedGoogle Scholar
  • 8 Luetscher JA, Boyers DG, Cuthbertson JG, McMahon DF. A model of the human circulation. Regulation by autonomic nervous system and renin-angiotensin system, and influence of blood volume on cardiac output and blood pressure. Circ Res 1973; 32: 84-98
    PubMedGoogle Scholar
  • 9 Brunner HR, Sealey JE, Laragh JH. Renin subgroups in essential hypertension. Further analysis of their pathophysiological and epidemiological characteristics. Circ Res 1973; 32: 99-105
    PubMedGoogle Scholar
  • 10 Alderman MH, Cohen HW, Sealey JE, Laragh JH. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17: 1-7
    CrossrefPubMedGoogle Scholar
  • 11 Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Bühler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441-449
    CrossrefPubMedGoogle Scholar
  • 12 Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-1104
    CrossrefPubMedGoogle Scholar
  • 13 Gonzalez MC, Cohen HW, Sealey JE, Laragh JH, Alderman MH. Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens 2011; 24: 1181-1186
    CrossrefPubMedGoogle Scholar
  • 14 Tomaschitz A, Pilz S, Ritz E, Morganti A, Grammer T, Amrein K, Boehm BO, März W. Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. Eur Heart J 2011; 32: 2642-2649
    CrossrefPubMedGoogle Scholar
  • 15 Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, Inenaga T, Kimura G. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 1997; 350: 1734-1737
    CrossrefPubMedGoogle Scholar
  • 16 Mulatero P, Verhovez A, Morello F, Veglio F. Diagnosis and treatment of low-renin hypertension. Clin Endocrinol (Oxf) 2007; 67: 324-334
    Google Scholar
  • 17 Verhovez A, Mulatero P, Bertello C, Saglio E, Viola A, Tosello F, Rabbia F, Veglio F. Is Renin-Based Treatment a Reasonable Strategy to Treat Essential Hypertension?. High Blood Press Cardiovasc Prev 2008; 15: 1-5
    CrossrefPubMedGoogle Scholar
  • 18 Spence JD. Stepped care for hypertension is dead, but what will replace it?. CMAJ 1989; 140: 1133-1136
    PubMedGoogle Scholar
  • 19 Spence JD. Government guidelines for treatment of hypertension. Am J Hypertens 1995; 8: 541
    CrossrefPubMedGoogle Scholar
  • 20 Garovic VD, Textor SC. Renovascular hypertension and ischemic nephropathy. Circulation 2005; 112: 1362-1374
    CrossrefPubMedGoogle Scholar
  • 21 Song AL, Zeng ZP, Tong AL, Lu L, Chen S, Li M, Fu CL, Wang YH, Sun ML. Differences of blood plasma renin activity, angiotensin II and aldosterone levels in essential or secondary hypertension. (Article in Chinese) Zhonghua Nei Ke Za Zhi 2012; 51: 294-298
    PubMedGoogle Scholar
  • 22 Bernini M, Bacca A, Casto G, Carli V, Cupisti A, Carrara D, Farnesi I, Barsotti G, Naccarato AG, Bernini G. A case of pheochromocytoma presenting as secondary hyperaldosteronism, hyperparathyroidism, diabetes and proteinuric renal disease. Nephrol Dial Transplant 2011; 26: 1104-1107
    CrossrefPubMedGoogle Scholar
  • 23 Laragh JH. Oral contraceptives – induced hypertension – nine years later. Am J Obstet Gynecol 1976; 126: 141-147
    CrossrefPubMedGoogle Scholar
  • 24 McVicar M, Carman C, Chandra M, Abbi RJ, Teichberg S, Kahn E. Hypertension secondary to renin-secreting juxtaglomerular cell tumor: case report and review of 38 cases. Pediatr Nephrol 1993; 7: 404-412
    CrossrefPubMedGoogle Scholar
  • 25 Muller FB, Sealey JE, Case DB, Atlas SA, Pickering TG, Pecker MS, Preibisz JJ, Laragh JH. The captopril test for identifying renovascular disease in hypertensive patients. Am J Med 1986; 80: 633-644
    CrossrefPubMedGoogle Scholar
  • 26 Rossi GP, Pavan E, Chiesura-Corona M, Bader M, Paganini G, Cesari M, De Toni R, Feltrin GP, Ganten D, Pessina AC. Renovascular hypertension with low-to-normal plasma renin: clinical and angiographic features. Clin Sci (Lond) 1997; 93: 435-443
    CrossrefPubMedGoogle Scholar
  • 27 Lenz T, Kia T, Rupprecht G, Schulte KL, Geiger H. Captopril test: time over?. J Hum Hypertens 1999; 13: 431-435
    CrossrefPubMedGoogle Scholar
  • 28 Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104: 545-556
    CrossrefPubMedGoogle Scholar
  • 29 Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193-202
    CrossrefPubMedGoogle Scholar
  • 30 Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897-902
    CrossrefPubMedGoogle Scholar
  • 31 Gordon RD, Laragh JH, Funder JW. Low renin hypertensive states: perspectives, unsolved problems, future research. Trends Endocrinol Metab 2005; 16: 108-113
    CrossrefPubMedGoogle Scholar
  • 32 Sealey JE, Gerten JN, Ledingham JG, Laragh JH. Inhibition of renin by heparin. J Clin Endocrinol Metab 1967; 27: 699-705
    CrossrefPubMedGoogle Scholar
  • 33 Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003; 88: 2384-2392
    CrossrefPubMedGoogle Scholar
  • 34 Cicala MV, Mantero F. Hypertension in Cushing’s syndrome: from pathogenesis to treatment. Neuroendocrinology 2010; 92: 44-49
    CrossrefPubMedGoogle Scholar
  • 35 Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, Lifton RP. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289: 119-123
    CrossrefPubMedGoogle Scholar
  • 36 Warnock DG. Liddle syndrome: an autosomal dominant form of human hypertension. Kidney Int 1998; 53: 18-24
    CrossrefPubMedGoogle Scholar
  • 37 Wilson RC, Nimkarn S, New MI. Apparent mineralocorticoid excess. Trends Endocrinol Metab 2001; 12: 104-111
    CrossrefPubMedGoogle Scholar
  • 38 Stratakis CA, Karl M, Schulte HM, Chrousos GP. Glucocorticosteroid resistance in humans. Elucidation of the molecular mechanisms and implications for pathophysiology. Ann N Y Acad Sci 1994; 746: 362-376
    PubMedGoogle Scholar
  • 39 Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. J Clin Endocrinol Metab 1983; 56: 222-229
    CrossrefPubMedGoogle Scholar
  • 40 Takeda Y, Yoneda T, Demura M, Furukawa K, Koshida H, Miyamori I, Mabuchi H. Genetic analysis of the cytochrome P-450c17alpha (CYP17) and aldosterone synthase (CYP11B2) in Japanese patients with 17alpha-hydroxylase deficiency. Clin Endocrinol (Oxf) 2001; 54: 751-758
    CrossrefPubMedGoogle Scholar
  • 41 Hadchouel J, Delaloy C, Fauré S, Achard JM, Jeunemaitre X. Familial hyperkalemic hypertension. J Am Soc Nephrol 2006; 17: 208-217
    PubMedGoogle Scholar
  • 42 Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, Tikhonova IR, Bjornson R, Mane SM, Colussi G, Lebel M, Gordon RD, Semmekrot BA, Poujol A, Välimäki MJ, De Ferrari ME, Sanjad SA, Gutkin M, Karet FE, Tucci JR, Stockigt JR, Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML, Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW, Hunley TE, Nelson RD, Trachtman H, Cole TR, Pinsk M, Bockenhauer D, Shenoy M, Vaidyanathan P, Foreman JW, Rasoulpour M, Thameem F, Al-Shahrouri HZ, Radhakrishnan J, Gharavi AG, Goilav B, Lifton RP. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 2012; 482: 98-102
    CrossrefPubMedGoogle Scholar
  • 43 Stowasser M, Pimenta E, Gordon RD. Familial or genetic primary aldosteronism and Gordon syndrome. Endocrinol Metab Clin North Am 2011; 40: 343-368
    CrossrefPubMedGoogle Scholar
  • 44 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM. Endocrine Society . Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281
    Google Scholar
  • 45 Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies – a review of the current literature. Horm Metab Res 2012; 44: 157-162
    Google Scholar
  • 46 Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-85
    Google Scholar
  • 47 Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, Crudo V, Burrello J, Milan A, Rabbia F, Veglio F. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 2013; 98: 4826-4833
    Google Scholar
  • 48 Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, Anderson RJ. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA 1998; 280: 1168-1172
    CrossrefPubMedGoogle Scholar
  • 49 Bühler FR, Laragh JH, Baer L, Vaughan Jr ED, Brunner HR. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972; 287: 1209-1214
    CrossrefPubMedGoogle Scholar
  • 50 Adlin EV, Marks AD, Channick BJ. Spironolactone and hydrochlorothiazide in essential hypertension. Blood pressure response and plasma renin activity. Arch Intern Med 1972; 130: 855-858
    CrossrefPubMedGoogle Scholar
  • 51 Bühler FR, Burkart F, Lütold BE, Küng M, Marbet G, Pfisterer M. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol 1975; 36: 653-669
    CrossrefPubMedGoogle Scholar
  • 52 Stumpe KO, Overlack O. Diuretics, beta-blockers or both as treatment for essential hypertension. Br J Clin Pharmacol 1979; 7: 189S-197S
    CrossrefPubMedGoogle Scholar
  • 53 Veterans Administration Co-operative Study Group On Antihypertensive Agents . Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol 1982; 14: 97S-101S
    CrossrefPubMedGoogle Scholar
  • 54 Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, Sowers JR, Zemel MB, Curry C, Schoenberger J, Wright JT, Kirkendall W, Conradi EC, Jenkins P, McLean B, Massie B, Berenson G, Flamenbaum W. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150: 1707-1713
    CrossrefPubMedGoogle Scholar
  • 55 Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramierz EA, Henderson WG. for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents . Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-921
    CrossrefPubMedGoogle Scholar
  • 56 Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008-2013
    CrossrefPubMedGoogle Scholar
  • 57 Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS, Brown MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2002; 20: 771-777
    CrossrefPubMedGoogle Scholar
  • 58 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997
    CrossrefPubMedGoogle Scholar
  • 59 Gupta AK, Poulter NR, Dobson J, Eldridge S, Cappuccio FP, Caulfield M, Collier D, Cruickshank JK, Sever PS, Feder G. ASCOT . Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial. Am J Hypertens 2010; 23: 1023-1030
    CrossrefPubMedGoogle Scholar
  • 60 Philipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. BMJ 1997; 315: 154-159
    CrossrefPubMedGoogle Scholar
  • 61 Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulter NR, Russell GI, Thom S, Williams B. Executive Committee, British Hypertension Society. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003; 17: 81-86
    CrossrefPubMedGoogle Scholar
  • 62 Vaughan Jr ED, Laragh JH, Gavras I, Bühler FR, Gavras H, Brunner HR, Baer L. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol 1973; 32: 523-532
    CrossrefPubMedGoogle Scholar
  • 63 Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan Jr ED. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52: 633-652
    CrossrefPubMedGoogle Scholar
  • 64 Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens 2011; 24: 1164-1180
    CrossrefPubMedGoogle Scholar
  • 65 Sealey JE, Parra D, Rosenstein R, Laragh JH. “Effective” plasma renin activity: a derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Hypertension 2010; 55: e16
    CrossrefPubMedGoogle Scholar
  • 66 Cody RJ, Laragh JH, Case DB, Atlas SA. Renin system activity as a determinant of response to treatment in hypertensionand heart failure. Hypertension 1983; 5: III36-III42
    PubMedGoogle Scholar
  • 67 Woods JW, Pittman AW, Pulliam CC, Werk Jr. EE, Waider W, Allen CA. Renin profiling in hypertension and its use in treatment with propranolol and chlorthalidone. N Engl J Med 1976; 294: 1137-1143
    CrossrefPubMedGoogle Scholar
  • 68 Pedersen EB, Kornerup HJ. Plasma renin concentration in essential hypertension during beta-adrenergic blockade and vasodilator therapy. Eur J Clin Pharmacol 1977; 12: 93-96
    CrossrefPubMedGoogle Scholar
  • 69 Nilsson OR, Karlberg BE, Ohlsson O, Thulin T, Tolagen K. Atenolol administered once daily in primary hypertension. Effects on blood pressure in relation to pre-treatment plasma renin activity. Acta Med Scand 1979; 206: 303-308
    PubMedGoogle Scholar
  • 70 Wyndham RN, Gimenez L, Walker WG, Whelton PK, Russell RP. Influence of renin levels on the treatment of essential hypertension with thiazide diuretics. Arch Intern Med 1987; 147: 1021-1025
    CrossrefPubMedGoogle Scholar
  • 71 Weir MR, Saunders E. Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans. Trandolapril Multicenter Study Group. J Hum Hypertens 1998; 12: 189-194
    CrossrefPubMedGoogle Scholar
  • 72 Minami J, Ishimitsu T, Matsuoka H. Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension. Am J Hypertens 2008; 21: 10-13
    CrossrefPubMedGoogle Scholar
  • 73 Minami J, Ohno E, Furukata S, Ishimitsu T, Matsuoka H. Pretreatment levels of plasma renin activity predict ambulatory blood pressure response to valsartan in essential hypertension. J Hum Hypertens 2009; 23: 683-686
    CrossrefPubMedGoogle Scholar
  • 74 Chrysant SG, Danisa K, Kem DC, Dillard BL, Smith WJ, Frohlich ED. Racial differences in pressure, volume and renin interrelationships in essential hypertension. Hypertension 1979; 1: 136-141
    CrossrefPubMedGoogle Scholar
  • 75 Schwartz GL, Bailey K, Chapman AB, Boerwinkle E, Turner ST. The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension. Am J Hypertens 2013; 26: 957-964
    CrossrefPubMedGoogle Scholar
  • 76 Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, Boerwinkle E, Johnson JA, Bailey KR. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 2010; 23: 1014-1022
    CrossrefPubMedGoogle Scholar
  • 77 Suonsyrjä T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Donner K, Strandberg T, Tikkanen I, Tilvis R, Pentikäinen PJ, Kontula K, Hiltunen TP. Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. J Hypertens 2008; 26: 1250-1256
    CrossrefPubMedGoogle Scholar
  • 78 Weintraub HS, Duprez DA, Cushman WC, Zappe DH, Purkayastha D, Samuel R, Izzo Jr JL. Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity. Cardiovasc Drugs Ther 2012; 26: 145-155
    CrossrefPubMedGoogle Scholar
  • 79 Leotta G, Rabbia F, Testa E, Totaro S, Abram S, Milan A, Mulatero P, Veglio F. Efficacy of antihypertensive treatment based on plasma renin activity: An open label observational study. Blood Press 2010; 19: 218-224
    CrossrefPubMedGoogle Scholar
  • 80 Egan BM, Basile JN, Rehman SU, Davis PB, Grob 3rd CH, Riehle JF, Walters CA, Lackland DT, Merali C, Sealey JE, Laragh JH. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens 2009; 22: 792-801
    CrossrefPubMedGoogle Scholar
  • 81 Blumenfeld JD, Laragh JH. Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens 1998; 11: 894-896
    CrossrefPubMedGoogle Scholar
  • 82 Smith SM, Campbell JD. Cost-Effectiveness of Renin-Guided Treatment of Hypertension. Am J Hypertens 2013; 26: 1303-1310
    CrossrefPubMedGoogle Scholar
  • 83 Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357
    CrossrefPubMedGoogle Scholar
  • 84 James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith Jr SC, Svetkey LP, Taler SJ, Townsend RR, Wright Jr JT, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520
    CrossrefPubMedGoogle Scholar
  • 85 Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S. British Hypertension Society . Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185
    CrossrefPubMedGoogle Scholar
  • 86 Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24: 2131-2141
    CrossrefPubMedGoogle Scholar
  • 87 Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-207
    CrossrefPubMedGoogle Scholar
  • 88 ONTARGET Investigators . Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
    CrossrefPubMedGoogle Scholar
  • 89 National Institute for Health and Clinical Excellence – National Clinical Guideline Centre. Clinical Guideline 127. Hypertension – The clinical management of primary hypertension in adults. August 2011. Available at www.nice.org.uk/guidance/CG127 (accessed online on 24th, March 2014)
    PubMedGoogle Scholar
  • 90 Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, Proschan MA, Thadani U, Whelton PK, Wright JT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group . Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006; 48: 374-384
    CrossrefPubMedGoogle Scholar
  • 91 Alderman MH, Cohen HW, Sealey JE, Laragh JH. Pressor responses to antihypertensive drug types. Am J Hypertens 2010; 23: 1031-1037
    CrossrefPubMedGoogle Scholar